Milena M. Petrovic

Milena M. Petrovic

Auto-generated profile, based on publicly available information

Milena M. Petrovic

Department of Chemistry Faculty of Science University of Kragujevac R. Domanovica 12 34000 Kragujevac Serbia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in ChemMedChem
Verified
Journal Article
Closed access
MPMilena M. Petrović
Milena M. Petrović
TATina Andrejević
Tina Andrejević
ŽMŽiko Milanović
Žiko Milanović
KMKristina Milisavljević
Kristina Milisavljević
TSTatjana Stanojković
Tatjana Stanojković
VMVioleta Marković
Violeta Marković

30 September 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VFVasileios Fougiaxis
Vasileios Fougiaxis
VBValentina Barcherini
Valentina Barcherini
MPMilena M. Petrovic
Milena M. Petrovic
PSPierre Sierocki
Pierre Sierocki
SWSandrine Warenghem
Sandrine Warenghem
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) by small-molecules is being eagerly investigated for the treatment of various autoimmune diseases and in the field of immuno-oncology after its active involvement in antigen presentation and processing. Currently, ERAP1 inhibitors are at different stages of clinical development, which highlights its significance as a promising drug target. In the present work, we describe the first-ever successful identification of several ERAP1 inhibitors derived from a fragment-based screening approach. We applied an enzymatic activity assay to a large library of ∼3000 fragment entries in order to retrieve 32 hits. After a multi-faceted selection process, we prioritized 3 chemotypes for SAR optimization and strategic modifications provided 2 series (2-thienylacetic acid and rhodanine scaffolds) with improved analogues at the low micromolar range of ERAP1 inhibition. We report also evidence of selectivity against homologous aminopeptidase IRAP, combined with complementary in silico docking studies to predict the binding mode and site of inhibition. Our compounds can be the starting point for future fragment growing and rational drug development, incorporating new chemical modalities.